Willkommen auf der Webseite der Medizinischen Klinik III für Hämatologie-Onkologie der Uniklinik Bonn

 Montag bis Freitag - 8:00 - 15:00 Uhr | Sprechzeit: nach Vereinbarung


   Zentrale: +49 (0) 228 287 170 50 Dienstarzt: +49 (0) 151 / 582 337 10

Prof. Dr. Dominik Wolf

Studium
1994 – 2000 Medical Training at the University of Erlangen- Nürnberg

Dissertation:
Summa cum laude“ unterstützt durch die DFG (Graduiertenkolleg).

Klinischer Werdegang:
2001-2007 Ausbildung zum Internisten, Medizinische Universität Innsbruck, Österreich
2008 Habilitation (“venia legendi”) für Innere Medizin
2009 Zusatzbezeichnung Hämatologie und Internistische Onkologie
2011 Ruf auf die W2 Professor für Tumorimmunologie und Oberarzt der Medizinischen Klinik 3, Onkologie, Hämatologie, Rheumatologie und Tumorimmunologie, Universitätsklinik (UKB) Bonn
2012 Leiter des KMT-Programms
2013 Leiter der Studienambulanz
2013 Bestellung zum Stv. Klinikdirektor

Forschungsschwerpunkte:
Immunregulation bei Krebs und Transplantation
Entzündung bei Myeloischen Erkrankungen

Klinische Schwerpunkte:
Immunonkologie
Myeloische Neoplasien (Akute Leukämie und MPN)
Stammzell-Transplantation

Preise:
Staedtler-Foundation 2002
Austrian Society of Nephrology 2005
Schönmann Krebsforschungspreis 2007
Otto-Kraupp-Gedächtnispreis (Sanofi-Aventis Preis) 2009
OEGHO Young Investigator 2013 (Senior)

Reviewer
Journale (Auswahl):
The Lancet, Cancer Discovery, Leukemia, Gut, Cancer Res, Clin Cancer Res, Cell Death Differentiation, Journal of the American Society of Nephrology, Haematologica, Molecular Cancer Therapeutics, Int J Cancer, Br J Haematol.

Förderprogramme:
Cancer Research UK, Worldwide Cancer Research, Deutsche Forschungsgemeinschaft (DFG), Swiss National Science Foundation, Forschungsfonds der Österreichischen Nationalbank, Wilhelm-Sander Stiftung

Mitgliedschaften:
American Society of Hematology (ASH)
European Society of Hematology (EHA)
Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)#
Österreichische Gesellschaft für Hämatologie und Onkologie (ASHO)

Patente:
Co-applicant: METHOD FOR INCREASING IMMUNOREACTIVITY (WO/2009/073905)
Co-applicant: METHOD FOR DETERMNING CBL-B EXPRESSION (WO/2010/119061 A1)

Klinische Studien:
PI verschiedener Industrie und akademischer Phase I bis Phase III Studien
Leitgrupe der German Study Group MPN (GSG-MPN)
Executive Committee der Central European Leukemia Study Group (CELSG)

Forschungsförderung (Auswahl):
DFG, FFG, OENB, OEGHO, Bonfor

List of Publications

Original articles:
  1. Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).
    Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.J Hematol Oncol. 2016 Mar 5;9(1):18.
  2. Held S, Heine A, Kesper AR, Schönberg K, Beckers A, Wolf D, Brossart P. Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors . 2015 Jul 1;5(1):e1065368. eCollection 2016.
  3. Hermann-Kleiter N, Klepsch V, Wallner S, Siegmund K, Klepsch S, Tuzlak S, Villunger A, Kaminski S, Pfeifhofer-Obermair C, Gruber T, Wolf D, Baier G. The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Rep. 2015 Sep 29;12(12):2072-85.
  4. Boesch M, Wolf D, Sopper S. Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype. Stem Cells Int. 2016;2016:1652389. doi: 10.1155/2016/1652389. Epub 2015 Dec 20.
  5. Klein S, Rick J, Lehmann J, Schierwagen R, Schierwagen IG, Verbeke L, Hittatiya K, Uschner FE, Manekeller S, Strassburg CP, Wagner KU, Sayeski PP, Wolf D, Laleman W, Sauerbruch T, Trebicka J. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut. 2015 Sep 17. pii: gutjnl-2015-309600. doi: 10.1136/gutjnl-2015-309600. [Epub ahead of print] PubMed PMID: 26385087.
  6. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762-9.
  7. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062-8.
  8. Boesch M, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D. Drug transporter-mediated protection of cancer stem cells from ionophore antibiotics. Stem Cells Transl Med. 2015 Sep;4(9):1028-32.
  9. Schönberg K, Rudolph J, Vonnahme M, Yajnanarayana SP, Cornez I, Hejazi M, Manser A, Uhrberg M, Verbeek W, Koschmieder S, Brümmendorf TH, Brossart P, Heine A, Wolf D. JAK inhibition substantially impairs NK cell function in vitro and in patients with myeloproliferative neoplasms (MPN) . Cancer Res. 2015 Apr 1. pii: canres.3198.2014. [Epub ahead of print]
  10. Holtick U, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, Fiedler A, Luznik L, Hellmich M, Wolf D, Hallek M, von Bergwelt M, Scheid C. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Hematol. 2016 Jan;96(1):27-35.
  11. Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke, Heine A, Brossart P, Kröger N, Wolf D. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015 Jun;169(6):824-33.
  12. Them N, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl G, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. American Journal of Hematology. 2015 Apr;90(4):288-94.
  13. Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G. Treatment of AML or MDSrelapse after allogeneic stem cell transplantation with Azacitidine and Donor Lymphocyte Infusions – a retrospective multicenter analysis of 154 patients on behalf of the German Cooperative Transplant Study Group. Biol Blood Marrow Transpl. 2015 Apr;21(4):653-60.
  14. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G , Siebert U. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leuk Lymphoma. Nov 13:1-40.
  15. Theurl M, Schgoer S, Albrecht-Schgoer K, Lener D, Wolf D, Wolf AM, Demetz E, Tymoszuk P, Tancevski I, Fischer-Colbrie R, Franz WM, Marschang P, Kirchmair R. Secretoneurin Gene Therapy Improves Hind Limb and Cardiac Ischemia in Apo E -/- mice Without Influencing Systemic Atherosclerosis. Res. 2015 Jan 1;105(1):96-106.
  16. Boesch M, Reimer D, Schmidt S, Parson W, SpoeckF, Hatina J, Zeimet AG, Wolf D*, Sopper S*. The Side Population of Ovarian Cancer Cells Exhibits Stem Cell Characteristics Despite Being Phenotypically Highly Heterogenous. Oncotarget. 2014 Aug 30;5(16):7027-39. (*these authors contributed equally)
  17. Pircher A, Gamerith G, Amann A, Reinold S, Popper S, Gaechter A, Gastl G, Wolf AM, Hilbe W, Wolf D. Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2014 Jul;85(1):81-7.
  18. Busch A, Zeh D, Janzen V, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal Lenalidomide induces effector central memory T cells, mature regulatory T cells and a novel monocytic MDSC population in myeloma patients. Clin Exp Immunol. 2014 Aug;177(2):439-53.
  19. Tancevski I, Nairz M, Duwensee K, Auer K, Schroll A, Heim C, Feistritzer C, Hoefer J, Heller I, Pallweber P, Li X, Theurl M, Demetz E, Wolf AM, Wolf D, Eller P, Ritsch A, Weiss G. Fibrates lower sepsis-driven mortality by enhancing neutrophil recruitment to the site of infection. EMBO Mol Med. 2014 Apr 22;6(6):810-20.
  20. Paolino M, Kerbl B, Wallner S, Pranjic B, Loeser S, Jamieson AM, Nitsch R, Baier G, Wolf D, Ullrich A, Penninger JM. A novel Tyro3/Cbl-b inhibitory pathway in NK cells controls tumor metastases. Nature. 2014 Mar 27;507(7493):508-12.
  21. Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayasatha D, Woodman RC, Hofmann WK, Hehlmann R, Hochhaus A, Müller MC. MDR1 expression predicts outcome of Ph+ CML patients on second line nilotinib therapy after Imatinib failure. Leukemia. 2014 Jul;28(7):1478-85.
  22. Rochau U, Sroczynski G, Wolf D, Schmidt D, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U. Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukaemia. Leuk Lymphoma. 2014 Aug;55(8):1758-67.
  23. Heine A, Held S, Solveik D, Wallner S, Yajnanarayana S, Kurts K, Wolf D*, Brossart P*. The JAK 1/2-Inhibitor Ruxolitinib is a potent inhibitor of dendritic cell differentiation and function. Blood. 2013 Aug 15;122(7):1192-202. (*both authors contributed equally)
  24. Wallner S, Lutz-Nicoladoni C, Tripp C, Gastl G, Stoixner P, Baier G, Wolf D. The Role of the E3 Ligase Cbl-b in Murine Dendritic Cells (DC). PLOS One. 2013 Jun 6;8(6):e65178.
  25. Droeser RA, Obermann EC, Wolf AM, Wallner S, Wolf D*, Tzankov A*. Marginal FoxP3 Expression in Breast Cancer Epithelial Cells. Clinical Breast Cancer. 2013 Aug;13(4):264-70. (*both authors contributed equally)
  26. Gruber T, Hinterleitner R, Pfeifhofer-Obermair C, Lutz-Nicoladoni C. Tzankov A, Schuster M, Penninger J, Loibner H, Lametschwandtner G, Wolf D*, Baier G*. Augmentation of tumor vaccine efficacy by combination with adoptive transfer of ex vivo synthetic siRNA cblb-silenced CD8+ T lymphocytes. PLOS One. 2012;7(9):e44295. (*both authors contributed equally)
  27. Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Hatina J. Ovarian cancer stem cells. Neoplasma. 2012 2012;59(6):747-55. [Epub ahead of print]
  28. Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Grubinger T, Kwakkelstein M, Rancati F, Gastl G, Wolf D. High dose imatinib improves cytogenetic and molecular remissions in pre-treated Ph+/BCR-ABL+ CML chronic phase patients: Final results from the a randomized CELSG CML 11 Phase III CML 11 “ISTAHIT” Study. 2012 Oct; 97(10):1562-9. [Epub ahead of print]
  29. Boesch M, Reimer D, Rumpold H, Zeimet A, Sopper S, Wolf D. DyeCycle Violet (DCV) Used for Side Population Detection is a Substrate of P-Glycoprotein. Cytometry Part A. 2012 Jun;81(6):517-22.
  30. Sterlacci W, Wolf D, Savic F, Hilbe W, Schmid T, Jamnig H, Fiegl, M Tzankov A. TGF-beta plays a pivotal role in tumor immunology for surgically resected non-small cell lung cancer. Human Pathol. 2012 Mar;43(3):339-49.
  31. Lutz-Nicoladoni C, Wallner S, Stoizner P, Pircher M, Gruber T, Wolf AM, Gastl G, Penninger J, Baier G, Wolf D. Reinforcement of Cancer Immunotherapy by Adoptive Transfer of Cbl-b Deficient CTL combined with Dendritic Cell Vaccination. Immunol & Cell Biol. 2012 Jan;90(1):130-4.
  32. Eller K, Kirsch K, Wolf AM, Sopper S, Tagwerker A, Stanzl A, Wolf D, Patsch W, Rosenkranz AR, Eller P. Regulatory T cells reverse insulin resistance and diabetic nephropathy. Diabetes. 2011 Nov;60(11):2954-62.
  33. Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, Eller K, Wolf D, Seifert M, Sun CC, Babitt JL, Hong CC, Menhall T, Gearing P, Lin HY, Weiss G. Pharmacologic downregulation of hepcidin reverses anemia of chronic disease. Blood. 2011 Nov 3;118(18):4977-84.
  34. Eller K, Wolf D, Huber JM, Siebenhaar F, Mayer G, McKenzie ANJ, Maurer M, Rosenkranz AR, Wolf AM. Mast cell recruitment via Treg-derived IL-9 is indispensable for Treg-induced immune-suppression. J Immunol. 2011 Jan 1;186(1):83-91.
  35. Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; on behalf of the ASHO CML registry. First annual report of the Austrian CML registry. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66.
  36. Markus M, Schgoer W, Albrecht K, Jeschke, Egger M, Beer AGE, Vasiljevic D, Rong S, Wolf AM, Bahlmann FH, Patsch J, Wolf D, Schratzberger P, Mahata SK, Kirchmair R. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. Nov 26;107(11):1326-35.
  37. Zeimet AG, Reimer D, Schwentner L, Fuchs D, Wolf D, Fuith LC, Fiegl H, Concin N, Daxenbichler G, Marth C. Urinary neopterin does not reflect the local anti-tumor immune milieu in ovarian cancer. Cancer Immunol Immunother. 2010 Dec;59(12):1813-23.
  38. Wolf AM, Rumpold H, Reimer D, Marth C, Zeimet A, Wolf D. High IL-12 and IL-23 expression is associated with superior outcome in ovarian cancer. Gynecol Oncol. 2010 Sep;118(3):244-50.
  39. Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G. High dose imatinib improves cytogenetic and molecular remissions in pretreated Ph+/BCR-ABL+ CML chronic phase patients: First results from a randomized CELSG CML 11 Phase III ISTAHIT Study. 2010 Jun;95(6):908-13.
  40. Clausen J, Kircher B, Schumacher P, Hetzenauer G, Wolf D, Gastl G, Nachbaur D. Impact of missing-KIR-ligand expression on GvHD and survival after HLA-identical sibling SCT. Biol Blood Marrow Transplantation. 2010 Feb;16:273-280.
  41. Schgoer W, Theurl M, Jeschke J, Beer AGE, Albrecht K, Gander R, Rong S, Vasiljevic D, Egger M, Wolf AM, Frauscher F, Koller A, Tancevski I, Patsch JR, Schratzberger P, Piza-Katzer H, Ritsch A, Bahlmann FH, Fischer Colbrie R, Wolf D, Kirchmair R. Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide dependent mechanism. Circ Res. 2009 105(10):994-1002.
  42. Wolf AM, Eller K, Zeiser R, Dürr C, Gerlach UV, Sixt M, Markut L, Gastl G, Rosenkranz AR, Wolf D. The sphingosine 1-phosphate receptor agonist FTY720 is a potent inhibitor of regulatory T cell proliferation in vitro and in vivo. J Immunol. 2009 Sep 15;183(6):2353-60.
  43. Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedermair A, Wolf AM, Rumpold H, Müller-Holzner E, MArth C. Intratumoral interferon regulatory factor (IRF)-1 bit not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer. 2009 May 15;124(10):2353-60.
  44. Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kahls P, Geissler D, Greil R, Linkesch W, Thaler J, Gastl G. Diagnostic algorithms, monitoring, prognostication and terhapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Klin, Wochenschr 2008; 120(21-22): 697-709.
  45. Metzler B, Channon K, Haubner B, Jehle J, Baur M, Wolf D, Pachinger O, Xu G. Myocardial Ischemia/Reperfusion Injury in Hematopoietic Cell-Restricted b1 Integrin Knockout Mice. Exp Physiol. 2008 Jul;93(7):825-33.
  46. Rumpold H, Salvador C, Wolf AM, Gastl G, Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun. 2007 Sep 21;361(2):549-54.
  47. Clausen J, Wolf D, Petzer AL, Gunsilius E, Gastl G, Nachbaur D. The Number of Natural Killer Cells in the Graft and the Risk of Relapse Following Allogeneic Stem Cell Transplantation. Clin Exp Immunol. 2007 Jun;148(3):520-8.
  48. Wolf D, Wolf AM, Fong D, Rumpold H, Strasak A, Clausen C, Nachbaur D. Treg in the graft and the risk of acute graft-versus-host disease following allogeneic stem cell transplantation. 2007; 83(8):1107-13.
  49. Bonaros N, Rauf R, Wolf D, Margreiter E, Tzankov A, Schlechta B, Kocher A, Schachner T, Hering S, Bonatti J, Laufer G. Combined Transplantation of sceletal myoblasts and angiopoietic progenitor cells reduces infarct size, apoptosis and improves cardiac function in a model of chronic ischemic heart failure. J Thorac Cardiov Sur. 2006 Dec;132(6):1321-8.
  50. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. Zoledronic Acid modulates myeloid cell function. 2006 Sep;91(9):1165-71.
  51. Untergasser G, Koeck R, Wolf D, Rumpold H, Ott H, Debbage P, KoppelstaetterC, Gunsilius E. CD34+/CD133- Circulating Endothelial Precursor cells (CEP): Characterization, senescence and usage for therapeutic vasoregeneration. Exp Gerontol. 2006 Jun;41(6):600-8.
  52. Wolf D, Rumpold H, Koppelstätter C, Gastl G, Mayer G, Steurer M, Gunsilius E, Tilg H, Wolf AM. Telomere length of in vivo expanded CD4+CD25+ regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother. 2006 Oct;55(10):1198-208.
  53. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The Expression of the Regulatory T-cell specific Forkhead Box Transcription Factor FoxP3 is Associated with Poor Prognosis in Ovarian Cancer. Cancer Res. 2005 Dec 1;11(23):8326-31 (incl. Editorial)
  54. Wolf AM, Wolf D, Zaragoza MA, Moschen A, Enrich B, Rumpold H, Tilg H. Hepatoprotective effects of adiponectin in acute liver failure. J Hepatol. 2006 Mar;44(3):537-43.
  55. Wolf AM*, Wolf D*, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Tilg H. The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Human Myeloid Cells and Prevents TNF-dependent Hepatic Injury in Mice. Proc Natl Acad Sci. U.S.A. 2005 Sep 20;102(38):13622-7. (*contributed equally)
  56. Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D. Stable RNAi-mediated knock-down of P-glycoprotein by a transposon-based vector system restores Imatinib sensitivity. Exp Haematol. 2005 Jul;33(7):767-75.
  57. Wolf D, Hochegger K, Wolf AM, Rumpold H, Gastl G, Tilg H, Mayer G, Gunsilius E, Rosenkranz AR. CD4+CD25+ Regulatory T-cells Inhibit Experimental anti-GBM Glomerulonephritis in Mice. J Am Soc Nephrol. 2005 May;16(5):1360-70. (incl. Editorial)
  58. Wolf AM, Wolf D, Rumpold H, enrich B, Tilg H. Adiponectin Inducesthe Anti-Inflammatory Cytokines Interleukin-10 and Interleukin-1 Receptor Antagonist in Human Leukocytes. Biochem Biophys Res Commun. Oct 15;323(2):630-5.
  59. Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P and Tilg H. Overexpression of Indoleamine 2,3-Dioxygenase (IDO) in Human Inflammatory Bowel Disease. Clin Immunol. 2004 Oct;113 (1):47-55.
  60. Ott HC, Bonaros N, Marksteiner R, Wolf D, Margreiter E, Schachner T, Laufer G and Hering S. Combined transplantation of skeletal myoblasts and bone marrow stem cells for myocardial repair in rats. Eur J Cardiothorac Surg. 2004 Apr; 25(4):627-634.
  61. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T-cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003 Feb;9(2):606-12.
  62. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Mergreiter R, Obrist P. Ep-Cam and Cox-2 overexpression predicts poor survival in breast cancer patients. Br J Cancer. 2003 Feb;88(4):574-8.
  63. Wolf D, Schumann J, Koerber K, Kiemer AK, Vollmar AM, Sass G, Papadopoulos T, Bang R, Klein SD, Brune B, Tiegs G. Low-molecular-weight hyaluronic acid induces nuclear factor-kappaB-dependent resistance against tumor necrosis factor alpha-mediated liver injury in mice. Hepatology. 2001 Sep;34(3):535-47.
  64. Wolf D , Hallmann R, Sass G, Sixt M, Kusters S, Fregien B, Trautwein C, Tiegs G. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1 – relevance for concanavalin A-induced hepatitis. J Immunol. 2001 Jan 15;166(2):1300-7.
  65. Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol. 2000 Nov;157(5):1671-83.
Reviews/Editorials:
  1. Schönberg K, Rudolph J, Parampalli Yajnanarayana S, Wolf D. Get a grip on immune-cells by inhibiting JAKs. Oncoimmunology. In press.
  2. Wolf D, Mayer K. When and how to “FLAMSA-RIC” in AML? Eur J Haematol. 2015 Aug 24. doi: 10.1111/ejh.12676. [Epub ahead of print] PubMed PMID: 26301717.
  3. Schönberg K, Rudolph J, Wolf D. NK cell modulation by JAK inhibition. Oncoscience. 2015 Aug 31;2(8):677-8.
  4. Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM. Treg(s) in cancer: Friends or Foe?. J Cell Physiol. 2015 Nov;230(11):2598-605.
  5. Wolf D, Wolf AM. CCR 20th Anniversary Commentary: From Regulatory T cells to Checkpoint Monoclonal Antibodies — Immuno-oncology Advances Clinical Cancer Research. Clin Cancer Res. 2015 Jun 15;21(12):2657-9.
  6. Lutz-Nicoladoni C, Wolf D, Sopper S. Modulation of immune cell functions by the E3 ligase CBL-b. Front Oncol. Mar 11;5:58. doi: 10.3389/fonc.2015.00058. eCollection 2015.
  7. Wolf D. Another piece of the puzzle – optimal TKI selection before treatment discontinuation in CML. Eur J Haematol. Mar;94(3):189-90.
  8. Valent P, Hadzijusufovic P, Holger-Schernthaner G, Wolf D, Rea D, le Coutre P. Vascular Safety Issues in CML Patients treated with BCR/ABL1 Kinase Inhibitors. Blood. 2015 Feb 5;125(6):901-6.
    Wolf D, Heine A, Brossart P. Implementation of combination therapy for immunotherapy of cancer – the concept of immunological conditioning. 2014 Jan 1;3(1):e27588.
  9. Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Systematic Assessment of Decision-analytic Models for Chronic Myeloid Leukemia. Applied Health Economics and Health Policy. 2014 Apr;12(2):103-15.
  10. Held S, Heine A, Mayer K, Wolf D, Brossart P. Immunotherapeutic approaches in CML. Current Cancer Drug Targets. 2013 Sep;13(7):768-74.
  11. Gruber T, Hinterleitner R, Pfeifhofer-Obermair C, Wolf D, Baier G. Engineering effective T cell-based anti-tumor immunity. Oncoimmunology. 2013 Feb 1;2(2):e22893.
  12. Wallner S, Gruber T, Baier G, Wolf D. Releasing the brake – Targeting Cbl-b to enhance lymphocyte effector function. Clin Dev Immunol. 2012;2012:692639.
  13. Wolf D. Ex vivo leukemia models and their potential clinical relevance. Int J Clin Pharmacol Ther. 2012 Jan;50(1):68-9.
  14. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Brossart P. Novel Treatment Concepts for Graft versus Host Disease (GvHD). Blood. 2012 Jan 5;119(1):16-25.
  15. Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer A, Pittermann E, Pleyer L, Thaler J, Wolf D. Nilotinib as Frontline Therapy in Chronic Myeloid Leukemia: Update and Recommendations. Crit Rev Oncol Hematol. 2012 Jun;82(3):370-7.
  16. J Rudzki, Wolf D. High dose Imatinib in CML-CP patients – is it still reasonable? Exp Rev Hematol. 2011 Apr;4(2):153-9.
  17. Wolf D, Rumpold H. Editorial – MPN Special Edition. Current Cancer Drug Targets. 2011 Jan 1;11(1):1-2.
  18. Wolf D, J Rudzki, Gastl G. Current Treatment Concepts of Philadelphia-negative myeloproliferative neoplasms (MPN). Current Cancer Drug Targets. 2011 Jan 1;11(1):44-55.
  19. Wolf D, Rumpold H. A Risk-Benefit Assessment of Imatinib in Chronic Myeloid Leukemia and Gastointestinal Stroma Tumors. Drug Safety. 2009; 32(11):1001-15.
  20. Schmidt S, Wolf D. The Role of Gene Expression Profiling in CML. Expert Rev Hematol. 2009 Feb;2(1):93-103
  21. Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet. 2008 May 10;371(9624):1553-4.
  22. Schmid S, Gastl G, Wolf D. The role of genetic profiling for CML response prediction. Leukemia and Lymphoma. 2008 Apr;49(4):643-7.
  23. Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. The kinase inhibitor Imatinib – an immunosuppressive drug? Curr Cancer Drug Targets. 2007 May;7(3):251-8.
  24. Wolf D, Rumpold H, Wolf AM. Regulatory T cells in cancer biology: a possible new target for biochemical therapies. Mini-Rev Med Chem. 2006 May;6(5):509-13.
  25. Eisendle K, Wolf D, Gastl G, Kircher B. Dendritic cells from patients with chronic myeloid leukaemia: functional and phenotypic features. Leuk Lymphoma. 2005 May;46(5):663-70.
  26. Rumpold H*, Wolf D*, Koeck R, Gunsilius E. Endothelial progenitor cells: A source for therapeutic vasculogenesis? J Cell Mol Med. 2004 Dec; 8 (4): 508.514. (*contributed equally)
Letter to the Editor/ Case Reports:
  1. Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK-1/2 Inhibitor Ruxolitinib controls a case of Chilblain Lupus Erythematosus. J Invest Dermatol. 2016 Feb 22. pii: S0022-202X(16)00500-5. doi: 10.1016/j.jid.2016.02.015. [Epub ahead of print] PubMed PMID: 26916391.
  2. Mayer K, Nellessen C, Hahn-Ast C, Schumacher M, Pietzonka S, Eis-Hübinger AM, Drosten C, Brossart P, Wolf D. Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN-alpha in a patient with newly diagnosed ALL. Eur J Haematol. 2016 Feb 8. doi: 10.1111/ejh.12744. [Epub ahead of print] PubMed PMID: 26854965.
  3. Hornung T, Wolf D, Wenzel J. More on remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2015 Mar 26;372(13):1274.
  4. Hornung T, JanzenV, Heidgen F, Wolf D, Bieber T, Wenzel J. Complete remission of concurrent Dermatomyositis in a Post-Polycythemia-Vera-Myelofibrosis Patient treated with the Janus-kinase-(JAK) inhibitor Ruxolitinib. N Engl J Med. 2014 Dec 25;371(26):2537-8.
  5. Schlitter MC, Rühl I, Thiesler T, Penner AH, Wolf D, Mayer K. Disseminated Intravascular Coagulation as First Clinical Manifestation of Splenic Littoral Cell Angioma. Ann Haematol. 2014 Oct;93(10):1795-6.
  6. Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N. JAK Inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post ET/PV myelofibrosis. Leukemia. 2014 Aug;28(8):1736-8.
  7. Mayer K, Gielen GH, Willinek W, Müller MC, Wolf D. Fatal progressive cerebral ischemia in CML under third-line treatment with Ponatinib. Leukemia. 2014 Apr;28(4):976-7.
  8. Mark W, Ollinger R, Rumpold H, Wolf D, Nachbaur D, Aigner F,Margreiter C, Gassner C, Schennach H, Graziadei I, Vogel W, Margreiter R, Gunsilius E. The liver graft as trojan horse-multilineage donor-derived hematopoiesis after liver transplantation: case report. Transplant Proc. 2013 Nov;45(9):3438-41.
  9. Heine A, Brossart P, Wolf D. Ruxolitinib is an immunosuppressive compound – is it time for prophylaxis? Blood. 2013 Nov 28;122(23):3843-4.
  10. C Schoenefeldt, K Sockel, R Wehner, S Sopper, D Wolf, M Wermke, C Thiede, U Oelschlaegel, G Ehninger, M Bornhaeuser, U Platzbecker, M Schmitz. Azacytidine impairs NK-cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation. Blood Cancer J. 2013 Aug 30;3:e136.
  11. Mayer K, Kapelle K, Weßling M, Bekeredjian-Ding I, Leutner C, von Lilienfeld-Toal M, Brossart P, Wolf D. Successful management of candida krusei monoarthritis after allogeneic stem cell transplantation. Bone Marrow Transpl. 2013 Jul 29. [Epub ahead of print]
  12. Pircher A, Gassner EA, Steurer M, Gunsilius E, Gastl G, Wolf D. Durable complete remission in a patient with recurrent diffuse large B-cell lymphoma (DLBCL) receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation. BMJ Case Rep. 2012 Jul 3;2012.
  13. Wolf D, Wolf AM, Tzankov A. Comment on “Cutting edge: Depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice”. J Immunol. 2010 Apr 15;184(8):4051
  14. Salvador C, Steurer S, Tzankov A, Wolf AM, Gastl G, Konwalinka G, Wolf D. Naturally occuring CD4+CD25+ regulatory T-cells modulate the hematopoietic potential of human stem cells in vitro. Br J Haematol. 2008 Sep;142(5):845-7. Epub 2008 Jul 8.
  15. Wolf AM, Rumpold H, Wolf D, Gastl G, Jenewein N, Marth C, Zeimet The role of FOXP3 expression in invasive breast cancer, J Clin Oncol. 2008 Oct 1;25(28):4499-500.
  16. Wolf D, Marth C, Wolf AM. Immune cells in colorectal cancer. N Engl J Med 2006 Apr 6;354(14):1531-2.
  17. Rumpold H, Wolf AM, Wolf D. The role of P-glycoporotein in imatinib resistance – a letter referring to the article by Zong et al. “P-glycoporotein does not confer imatinib resistance”. 2006 Jan;20(1):144.
  18. Krugmann J, Tzankov A, Dirnhofer S, Fend F, Wolf D, Siebert R, Probst P, Erdel M. Comment to: Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy. World J Gastroenterol. 2005 Dec 14;11(46):7384-5.
  19. Hochegger K, Wolf D, Rosenkranz A. Letter regarding the article by Javaid et al: Treatment of glomerulonephritis: Will we ever have options other than steroids and cytotoxics? Kidney Int. 2005 Oct;68(4):1898-9.
  20. Wolf D, Rumpold H, Gunsilius E. Letter regarding the article by Wojakowski et al, Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2005 May 24;111(20):307-8.
  21. Wolf D, Rumpold H, Köck R, Gunsilius E. Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents. J Nat Cancer Inst. 2005 Apr 6;97(7):540-1.
  22. Wolf D, Gastl G, Rumpold H. Complete Remission of a FIP1L1-PDGFRA negative Hypereosinophilic Syndrome by Imatinib (Glivec®). Dtsch Med Wochenschr. 2004 Oct 1;129(40):2104-6.

Original Article with listing as collaborator:
Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators.

Collaborators (58)
Gisslinger H, Greil R, Rumpold H, Wolf D, Knoops L, Bosly A, De Bock R, Delannoy A, Devos T, Van Droogenbroeck J, Van Eygen K, Zachee P, Demuynck H, Theunissen K, Kiladjian J-, Cahn J-, Cambier N, Cassadevall N, Dupriez B, Milpied N, Jourdan E, Leporrier M, Natarajan-Amé S, Récher C, Ribrag V, Vey N, Aulitzky W, Novotny J, Kindler T, Koschmieder S, Le Coutre P, Niederwieser D, Al-Ali H, Ottmann O, Scheid C, Sökler M, Lipka D, Barosi G, Passamonti F, Gambacorti-Passerini C, Cilloni D, Vannucchi AM, Pieri L, Pungolino E, Schaap N, Kluin-Nelemans JC, Schouten H, te Boekhorst P, Wijermans P, Cervantes F, Hernandez-Boluda J-, Ojeda E, Merup M, Johansson P, Harrison C, Green A, McMullin M, Vyas P. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014 Apr 3;123(14):2157-60. doi: 10.1182/blood-2013-11-536557. Epub 2014 Jan 23.

Book chapters
Wolf D. Zukünftige Therapiestrategien in der Behandlung der CML: CML. UniMed Verlag 2014.
Wolf D, Wolf AM. Lymphokine: Biologie und Anwendung in der Immuntherapie von Tumoren. Wachstumsfaktoren in der Hämato-Onkologie. UniMed Verlag 2010.
Wolf D, Stauder R. Management of Myeloproliferative Diseases in Senior Patients. ESMO Handbook of Cancer in the Senior Patient. Informa Healthcare. 2010.
Stauder R, Wolf D. Management of Myelodysplastic Syndromes in Senior Patients. ESMO Handbook of Cancer in the Senior Patient. Informa Healthcare. 2010.